TrialAmerican journal of clinical dermatology2023

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).

Ohsang Kwon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.